The Global Monoclonal Antibody Partnering Terms and
Agreements 2010 to 2017 report provides comprehensive understanding and
unprecedented access to the monoclonal antibodies partnering deals and
agreements entered into by the worlds leading healthcare companies
Description
The Global Monoclonal antibody Partnering Terms and
Agreements 2010 to 2017: Deal trends, players, financials and forecasts report
provides a detailed understanding and analysis of how and why companies enter
monoclonal antibody partnering deals. The majority of deals are development
stage whereby the licensee obtains a right or an option right to license the
licensors monoclonal antibody technology. These deals tend to be
multicomponent, starting with collaborative R&D, and commercialization of
outcomes.
This report provides details of the latest monoclonal
antibody agreements announced in the healthcare sectors, covering:
- Monoclonal antibodies
- Murine mAb
- Chimeric mAb
- Humanized mAb
- Human aAb
Understanding the flexibility of a prospective partner’s
negotiated deals terms provides critical insight into the negotiation process
in terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments clauses,
the devil is in the detail in terms of how payments are triggered – contract
documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all
monoclonal antibody partnering deals announced since Jan 2010, including
financial terms where available, including links to online deal records of
actual monoclonal antibody partnering deals as disclosed by the deal parties.
In addition, where available, records include contract documents as submitted
to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation
of monoclonal antibody dealmaking and business activities. Chapter 1 provides
an introduction to the report, whilst chapter 2 provides an overview of the
trends in monoclonal antibody dealmaking since 2010, including details of
average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading monoclonal
antibody deals since 2010. Deals are listed by headline value, signed by big
pharma, most active monoclonal antibody dealmaking companies. Where the deal
has an agreement contract published at the SEC a link provides online access to
the contract.
Chapter 4 provides a comprehensive listing of the top 25
most active companies in monoclonal antibody dealmaking with a brief summary
followed by a comprehensive listing of monoclonal antibody deals, as well as
contract documents available in the public domain. Where available, each deal
title links via Weblink to an online version of the actual contract document,
providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of
monoclonal antibody partnering deals signed and announced since Jan 2010, where
a contract document is available in the public domain. The chapter is organized
by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc),
and specific therapy focus. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of
monoclonal antibody partnering deals signed and announced since Jan 2010. The
chapter is organized by specific monoclonal antibody technology type in focus.
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
In addition, a comprehensive appendix is provided organized
by monoclonal antibody partnering company A-Z, deal type definitions and
monoclonal antibody partnering agreements example. Each deal title links via
Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate
the trends and activities in monoclonal antibody partnering and dealmaking
since 2010.
In conclusion, this report provides everything a prospective
dealmaker needs to know about partnering in the research, development and
commercialization of monoclonal antibody technologies and products.
Key benefits
Global Monoclonal antibody Partnering Terms and Agreements
2010 to 2017 provides the reader with the following key benefits:
- In-depth understanding of monoclonal antibodies deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Access to the structure of monoclonal antibodies agreements with numerous real life case studies
- Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world’s biopharma companies
- Identify the leading monoclonal antibody partnering companies
- Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Monoclonal antibody Partnering Terms and Agreements
2010 to 2017 is intended to provide the reader with an in- depth understanding
and access to monoclonal antibodies trends and structure of deals entered into
by leading companies worldwide.
Global Monoclonal antibody Partnering Terms and
Agreements 2010 to 2017 includes:
- Trends in monoclonal antibodies dealmaking in the biopharma industry since 2010
- Analysis of monoclonal antibodies deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 700 monoclonal antibodies deal records
- The leading monoclonal antibodies deals by value since 2010
- Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2010
In Global Monoclonal antibody Partnering Terms and
Agreements 2010 to 2017, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Monoclonal antibodies type
The Global Monoclonal Antibody Partnering Terms and
Agreements 2010 to 2017 report provides comprehensive access to available deals
and contract documents for over 700 monoclonal antibody deals.
Analyzing actual contract agreements allows assessment of
the following:
- What are the precise monoclonal antibody rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Global Monoclonal Antibody Partnering Terms and Agreements
2010 to 2017 provides the reader with the following key benefits:
- In-depth understanding of monoclonal antibodies deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Acces to the structure of monoclonal antibodies agreements with numerous real life case studies
- Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world’s biopharma companies, together with real world clause examples
- Full listing of monoclonal antibodies deals by company A-Z, deal value, phase of development, deal type, and therapy focus
- Identify leading monoclonal antibodies deals by value since 2010
- Identify the most active monoclonal antibodies dealmakers since 2010
- Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 500 pages “Global Monoclonal
Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and
financials” report
covers Executive Summary, Introduction, Trends in monoclonal antibody
dealmaking, Leading monoclonal antibody deals, Most active monoclonal antibody
dealmakers, Monoclonal antibody contracts dealmaking directory, Monoclonal
antibody dealmaking by technology type, Partnering resource center, Appendices.
For
more information Visit at: http://mrr.cm/UYo
Related Reports;
Global
Vaccine Partnering Terms and Agreements 2010-2016: Deal trends, players and
financials - Visit at - http://mrr.cm/UYJ
Global
Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and
financials - Visit at - http://mrr.cm/UY3
No comments:
Post a Comment
Note: only a member of this blog may post a comment.